NASDAQ:APVO - Aptevo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 398.59 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.22
▲ +0.11 (1.55%)

This chart shows the closing price for APVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptevo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APVO

Analyst Price Target is $36.00
▲ +398.59% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aptevo Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 398.59% upside from the last price of $7.22.

This chart shows the closing price for APVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Aptevo Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2021UBS GroupDowngradeBuy ➝ NeutralMedium
11/15/2021Roth CapitalLower Price TargetBuy$50.00 ➝ $36.00High
5/28/2021Roth CapitalLower Price TargetBuy$64.00 ➝ $50.00Low
11/11/2020Piper SandlerReiterated RatingOverweightLow
8/14/2020Piper SandlerBoost Price Target$24.00 ➝ $32.00High
5/15/2020Piper SandlerLower Price Target$24.00 ➝ $18.50Medium
3/4/2020Roth CapitalReiterated RatingBuyMedium
3/2/2020Piper SandlerLower Price Target$3.00 ➝ $1.70High
10/4/2019Piper Jaffray CompaniesLower Price Target$4.50 ➝ $3.00Low
5/23/2019Roth CapitalReiterated RatingBuyLow
4/15/2019Piper Jaffray CompaniesBoost Price TargetOverweight$4.00 ➝ $4.50Medium
3/13/2019Piper Jaffray CompaniesLower Price TargetOverweight$8.50 ➝ $4.00Low
11/15/2018Roth CapitalSet Price TargetBuy$12.00High
11/5/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$14.00Low
8/10/2018Piper Jaffray CompaniesReiterated RatingOverweight$11.00High
5/10/2018Piper Jaffray CompaniesBoost Price TargetOverweight$6.00 ➝ $9.00Low
4/11/2018Roth CapitalInitiated CoverageBuy$12.00High
10/5/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$6.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/18/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Aptevo Therapeutics logo
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
Read More

Today's Range

Now: $7.22
Low: $6.90
High: $7.24

50 Day Range

MA: $8.83
Low: $6.48
High: $17.03

52 Week Range

Now: $7.22
Low: $6.38
High: $43.21

Volume

73,423 shs

Average Volume

117,610 shs

Market Capitalization

$35.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

6.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptevo Therapeutics?

The following Wall Street research analysts have issued research reports on Aptevo Therapeutics in the last twelve months: Roth Capital, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for APVO.

What is the current price target for Aptevo Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Aptevo Therapeutics in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 398.6%. Roth Capital has the highest price target set, predicting APVO will reach $36.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $36.00 for Aptevo Therapeutics in the next year.
View the latest price targets for APVO.

What is the current consensus analyst rating for Aptevo Therapeutics?

Aptevo Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APVO will outperform the market and that investors should add to their positions of Aptevo Therapeutics.
View the latest ratings for APVO.

How do I contact Aptevo Therapeutics' investor relations team?

Aptevo Therapeutics' physical mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company's listed phone number is (206) 838-0500 and its investor relations email address is [email protected] The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.